Actively Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Led by Alexion Pharmaceuticals, Inc. · Updated on 2026-04-22
30
Participants Needed
40
Research Sites
94 weeks
Total Duration
On this page
Sponsors
A
Alexion Pharmaceuticals, Inc.
Lead Sponsor
A
AstraZeneca
Collaborating Sponsor
AI-Summary
What this Trial Is About
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
CONDITIONS
Official Title
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented diagnosis of Primary Membranous Nephropathy confirmed by positive anti-PLA2R antibody (> 20 RU/mL) at Screening
- Willingness to receive background Standard of Care (SoC)
- High risk for disease progression defined by: receiving ACE inhibitor or ARB for at least 8 weeks at maximally tolerated dose; systolic blood pressure <140 mmHg in ≥75% of readings in last 8 weeks; two proteinuria measurements each >3.5 g/day with the second showing ≤50% decrease from the first
- Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m² during Screening
- Must receive prophylactic antibiotics while on Rituximab and be willing to be vaccinated against Neisseria meningitidis
You will not qualify if you...
- Rapid deterioration of kidney function
- History of life-threatening Nephrotic Syndrome within 1 year before Screening
- Diagnosis of PLA2R-negative membranous nephropathy or anti-PLA2R positive MN with serum anti-PLA2R <20 RU/mL or kidney disease other than PMN
- History of or planned kidney transplant or dialysis during Treatment Period
- History of other solid organ or bone marrow transplant or planned transplant during Treatment Period
- Clinically relevant co-morbidities
- Intolerance or hypersensitivity to ACE inhibitors or ARBs
- Initiation or dose adjustment of SGLT2 inhibitors within 12 weeks prior to randomization or planned adjustment during treatment
- Use of traditional Chinese medicines with systemic immunosuppressive properties within 6 months prior to screening
- Use of mineralocorticoid receptor antagonists or endothelin receptor antagonists within 12 weeks prior to randomization and during study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 40 locations
1
Research Site
Loma Linda, California, United States, 92354
Actively Recruiting
2
Research Site
San Diego, California, United States, 92123
Actively Recruiting
3
Research Site
Minneapolis, Minnesota, United States, 55435
Actively Recruiting
4
Research Site
Rochester, Minnesota, United States, 55905
Actively Recruiting
5
Research Site
Houston, Texas, United States, 77030
Actively Recruiting
6
Research Site
Buenos Aires, Argentina, 1425
Actively Recruiting
7
Research Site
CABA, Argentina, C1425AGC
Actively Recruiting
8
Research Site
Ciudad de Buenos Aires, Argentina, 1280
Actively Recruiting
9
Research Site
La Plata, Argentina, B1902COS
Not Yet Recruiting
10
Research Site
Rosario, Argentina, 2000
Actively Recruiting
11
Research Site
Santa Fe, Argentina, S3000EOZ
Withdrawn
12
Research Site
Santa Fe, Argentina, S3000
Withdrawn
13
Research Site
Gosford, Australia, 2250
Actively Recruiting
14
Research Site
Parkville, Australia, 3050
Actively Recruiting
15
Research Site
Southport, Australia, 4222
Actively Recruiting
16
Research Site
Recife, Brazil, 50670-901
Actively Recruiting
17
Research Site
Salvador, Brazil, 40301-155
Actively Recruiting
18
Research Site
São Paulo, Brazil, 04038-002
Actively Recruiting
19
Research Site
São Paulo, Brazil, 05403-000
Actively Recruiting
20
Research Site
Baotou, China, 014010
Actively Recruiting
21
Research Site
Beijing, China, 100034
Actively Recruiting
22
Research Site
Guangzhou, China, 510080
Actively Recruiting
23
Research Site
Shenzhen, China, 518036
Actively Recruiting
24
Research Site
Créteil, France, 94010
Withdrawn
25
Research Site
Nice, France, 06000
Actively Recruiting
26
Research Site
Toulouse, France, 31059
Actively Recruiting
27
Research Site
Milan, Italy, 20122
Actively Recruiting
28
Research Site
Ranica, Italy, 24020
Actively Recruiting
29
Research Site
Torrette, Italy, 60126
Actively Recruiting
30
Research Site
Barcelona, Spain, 08025
Actively Recruiting
31
Research Site
Madrid, Spain, 28007
Actively Recruiting
32
Research Site
Seville, Spain, 41013
Actively Recruiting
33
Research Site
Toledo, Spain, 45007
Actively Recruiting
34
Research Site
Kaohsiung City, Taiwan, 81362
Actively Recruiting
35
Research Site
Taichung, Taiwan, 40705
Actively Recruiting
36
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
37
Research Site
Cambridge, United Kingdom, CB2 0QQ
Actively Recruiting
38
Research Site
Leicester, United Kingdom, LE5 4PW
Actively Recruiting
39
Research Site
London, United Kingdom, SE5 9RJ
Actively Recruiting
40
Research Site
Salford, United Kingdom, M6 8HD
Actively Recruiting
Research Team
A
Alexion Pharmaceuticals, Inc. (Sponsor)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here